Asked by: Lord Taylor of Warwick (Non-affiliated - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of current eligibility guidelines of BRCA1 gene testing, and how testing allows early detection of heightened risk of prostate cancer.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Genomic testing in the National Health Service in England is delivered in line with the National Genomic Test Directory. The test directory outlines eligibility criteria and testing methods for over 200 cancer indications, including BRCA1 and BRCA2 testing for prostate cancer, and is regularly reviewed through an evidence-based process to ensure testing remains clinically relevant and cost-effective. Testing for BRCA1 and BRCA2 can help identify individuals at increased genetic risk of developing prostate cancer, enabling earlier and more targeted monitoring, diagnosis, and treatment. This supports timely clinical interventions and can improve outcomes for patients and their families. NHS England has also funded transformation projects through NHS Genomic Medicine Service (GMS) alliances, including one led by the East GMS Alliance focused on improving the prostate cancer pathway. This project focused on the genetic testing of prostate tumour tissue samples to better understand the causes and inform treatment decisions, while also identifying whether relatives may be at increased risk of cancers such as breast, ovarian, or prostate cancer.
Asked by: Victoria Collins (Liberal Democrat - Harpenden and Berkhamsted)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to include targets on improving survival for (a) ovarian cancer and (b) other rare and less common cancers in the upcoming national cancer plan.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to improving survival outcomes for all cancer types, including ovarian cancer and other rare and less common cancers, by catching it early, and treating it faster and more effectively. As a first step, the National Health Service is now delivering an extra 40,000 operations, scans, and appointments each week, to support early diagnosis and faster treatment.
NHS England is continuing the roll out of community diagnostic centres to ensure that patients can access the diagnostic tests they need as quickly as possible. The NHS is also improving pathways to get people diagnosed faster once they are referred, including non-specific symptom pathways for patients who do not fit clearly into a single urgent cancer referral pathway.
To ensure patients have access to the best treatment for ovarian cancer, NHS England commissioned an audit on ovarian cancer. Using routine data collected on patients diagnosed with ovarian cancer in an NHS setting as part of their care and treatment, the audits bring together information to look at what is being done well, where it’s being done well, and what needs to be improved. The audit published its report in September 2024 and officials across NHS England and the Department are considering its findings.
Further actions on improving the survival of all cancers, including ovarian cancer and other rare and less common cancers, will be outlined in the forthcoming National Cancer Plan, which will be published later this year. It will seek to improve every aspect of cancer care to better the experience and outcomes for people with cancer. The goal is to reduce the number of lives lost to cancer over the next ten years, and the ambition will be set out as part of the National Cancer Plan.
Asked by: Victoria Collins (Liberal Democrat - Harpenden and Berkhamsted)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve survival outcomes for patients diagnosed with (a) ovarian cancer and (b) other rare and less common cancers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to improving survival outcomes for all cancer types, including ovarian cancer and other rare and less common cancers, by catching it early, and treating it faster and more effectively. As a first step, the National Health Service is now delivering an extra 40,000 operations, scans, and appointments each week, to support early diagnosis and faster treatment.
NHS England is continuing the roll out of community diagnostic centres to ensure that patients can access the diagnostic tests they need as quickly as possible. The NHS is also improving pathways to get people diagnosed faster once they are referred, including non-specific symptom pathways for patients who do not fit clearly into a single urgent cancer referral pathway.
To ensure patients have access to the best treatment for ovarian cancer, NHS England commissioned an audit on ovarian cancer. Using routine data collected on patients diagnosed with ovarian cancer in an NHS setting as part of their care and treatment, the audits bring together information to look at what is being done well, where it’s being done well, and what needs to be improved. The audit published its report in September 2024 and officials across NHS England and the Department are considering its findings.
Further actions on improving the survival of all cancers, including ovarian cancer and other rare and less common cancers, will be outlined in the forthcoming National Cancer Plan, which will be published later this year. It will seek to improve every aspect of cancer care to better the experience and outcomes for people with cancer. The goal is to reduce the number of lives lost to cancer over the next ten years, and the ambition will be set out as part of the National Cancer Plan.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make it his policy to establish a regular bladder cancer audit to (a) reduce data gaps in the reporting of (i) incidence and (ii) staging, (b) capture data on inequalities and (c) provide an evidence base for addressing unwarranted variation in early diagnosis and outcomes for bladder cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The NHS Cancer Programme commissioned the Royal College of Surgeons to deliver six new clinical audits, in primary breast cancer, metastatic breast cancer, ovarian cancer, pancreatic cancer, non-Hodgkin lymphoma, and kidney cancer, on top of four existing audits in bowel, lung, oesophago-gastric, and prostate cancer. These audits were chosen because analysts considered that they are the cancers which audits would have the most potential to reduce unwarranted variation in treatment and outcomes. For these reasons, there are no plans to undertake a clinical audit for bladder cancer.
The National Cancer Plan will include further details on how we will improve outcomes for cancer patients, including those with bladder cancer, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately bringing this country’s cancer survival rates back up to the standards of the best in the world.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, pursuant to the Answer of 27 June 2025 to Question 61211 on Asbestos: Ovarian Cancer, if she will direct the Health and Safety Executive to collect data on asbestos-related ovarian cancer cases.
Answered by Stephen Timms - Minister of State (Department for Work and Pensions)
Collecting data on individual cases of asbestos-related ovarian cancer is not feasible due to difficulties attributing them to historic exposure with confidence. Significant resource would be needed to produce estimates based on epidemiological evidence. These are likely to be small in comparison to other asbestos-related diseases such as mesothelioma (which is more clearly linked to past exposure) and would have considerable associated uncertainty.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to increase research funding for (a) ovarian, (b) uterine and (c) other gynaecological cancers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests in research through its research delivery arm, the National Institute for Health and Care Research (NIHR). In the period 2020/21 to 2024/25, the NIHR’s Academy and other programmes invested approximately £39 million across 50 gynaecological cancer research projects. The following table shows the number of awards and the value of the awards for each gynaecological cancer type:
Gynaecological cancer type | Number of awards | Awards value |
Cervical cancer | 17 | £15,200,000 |
Ovarian cancer | 17 | £6,300,000 |
Vulval cancer | 1 | £3,700 |
Womb (uterine) cancer | 10 | £3,600,000 |
More than 1 gynaecological type | 5 | £10,000,000 |
Grand total | 50 | £39,000,000 |
Additionally, the NIHR’s Research Delivery Network, which enables the health and care system to attract, optimise, and deliver research across England, and has supported 123 commercial studies and 148 non-commercial studies for gynaecological cancers covering the same period.
The NIHR funds research in response to proposals received. The NIHR continues to welcome high quality, high impact funding applications for research into any aspect of human health and care, including all gynaecological cancers.
Asked by: Victoria Collins (Liberal Democrat - Harpenden and Berkhamsted)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve timely access to innovative treatments for women with ovarian cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to improving cancer care for patients across England, including those with ovarian cancer. The National Cancer Plan will include further details on how we will improve outcomes for cancer patients across the country, including patients with ovarian cancer, as well as speeding up diagnosis and access to treatment. It will ensure that more patients have access to the latest treatments and technology, and to clinical trials. These actions will help bring this country’s cancer survival rates back up to the standards of the best in the world.
The Government is supporting Scott Arthur’s Private Members Bill on rare cancers. The bill will make it easier for clinical trials into rare cancers, such as ovarian cancer, to take place in England by ensuring the patient population can be easily contacted by researchers.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, if she will require the Health and Safety Executive to collect data on asbestos-related ovarian cancer cases.
Answered by Stephen Timms - Minister of State (Department for Work and Pensions)
The Health and Safety Executive (HSE) is responsible for collection of data of workplace injury and illness. Under Regulation 9 of the Reporting of Injuries, Diseases and Dangerous Occurrences Regulations 2013 (RIDDOR), it requires the responsible person to report a diagnosis of any cancer attributed to an occupational exposure to a known human carcinogen in their current job. When reporting, the responsible person must provide details on the affected person's occupation or job title and a description of the work that led to the disease.
Estimated numbers of cases of certain kinds of cancer other than mesothelioma and lung cancer that are attributable to past exposure to asbestos are available from previous HSE sponsored research into the burden of occupational cancer in Great Britain. However, ovarian cancer in relation to asbestos was not considered at the time this research was carried out, and so estimates are not currently available and HSE has no plans to collect this data.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he plans to take through the NHS 10 Year Plan to improve early diagnosis in (a) ovarian cancer and (b) other women’s health conditions.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to improving early diagnosis of all cancer types, including ovarian cancer.
The 10-Year Health Plan will deliver the three big shifts our National Health Service needs to be fit for the future: from hospital to community; from analogue to digital; and from sickness to prevention. All of these are relevant to improving early diagnosis and support for women’s health conditions in all parts of the country.
As a first step, the NHS is now delivering an extra 40,000 operations, scans, and appointments each week, to ensure early diagnosis and faster treatment, including for women with ovarian cancer. NHS England is continuing the roll out of community diagnostic centres to ensure that patients can access the diagnostic tests they need as quickly as possible. The NHS is also improving pathways to get people diagnosed faster once they are referred, including non-specific symptom pathways for patients who do not fit clearly into a single urgent cancer referral pathway. Combined, these interventions will help to improve the early diagnosis of ovarian cancer and reduce misdiagnosis, with further actions to be outlined in the forthcoming National Cancer Plan, which will follow the 10-Year Health Plan.
The Department is also committed to improving the diagnosis of women’s health conditions more broadly by taking urgent action to tackle gynaecology waiting lists through the Elective Reform Plan, supporting innovative models offering patients care closer to home, and by piloting gynaecology pathways in community diagnostic centres. Moreover, the Department supports the use of clinical guidelines that help healthcare professionals identify and manage these conditions. The National Institute for Health and Care Excellence has published guidelines on a range of women’s health conditions, including heavy menstrual bleeding, endometriosis, and menopause.
Asked by: Lord Markham (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking in the upcoming national cancer plan to identify and address regional disparities in the diagnosis and treatment of ovarian cancer.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
It is a priority for the Government to support the National Health Service to diagnose cancer, including ovarian cancer, as quickly as possible, to treat it faster, and to improve outcomes. This is supported by NHS England’s key ambition on cancer to meet the Faster Diagnosis Standard, which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out.
Reducing inequity and variation in cancer care is a priority for the Government, as is increasing early cancer diagnosis, as both are key contributors to reducing cancer health inequalities. Early cancer diagnosis is also a specific priority within the NHS’s wider Core20Plus5 approach to reducing healthcare inequalities.
In addition, we have committed to delivering an extra 40,000 operations, scans, and appointments each week, during our first year in Government as the first step to ensuring early diagnosis and faster treatment.
The recently announced National Cancer Plan will have patients at its heart and will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and aftercare. It will seek to improve every aspect of cancer care to improve the experience and outcomes for people with cancer. This will include improving levels of early diagnosis across England. Our goal is to reduce the number of lives lost to cancer over the next ten years, including to ovarian cancer.